GLP-1 Manufacturing Market Research Report

According to data analyzed by Insightorax, the global GLP-1 manufacturing market size was valued at USD 14.6 billion in 2026 and is projected to grow from USD 16.6 billion in 2027 to USD 46.4 billion by 2035, registering a CAGR of 13.7% during the 2026–2035 forecast period. North America accounted for the largest revenue share of 39.0% in 2026. Market growth is driven by rising demand for GLP-1-based therapies for obesity and type 2 diabetes, increasing diagnosis and treatment rates, expanding patient populations, and continued investment in peptide manufacturing capacity. Growing adoption of injectable and next-generation GLP-1 therapies, pharmaceutical outsourcing, technological advances in peptide synthesis and formulation, and efforts by manufacturers to scale production are further supporting demand. Increasing healthcare expenditure and broader access to metabolic treatments are also strengthening global manufacturing requirements.

The GLP-1 Manufacturing Market encompasses the production, processing, formulation, and supply of glucagon-like peptide-1 (GLP-1) receptor agonists and related metabolic therapeutics. The market covers manufacturing activities required to convert active pharmaceutical ingredients (APIs) and peptide intermediates into pharmaceutical-grade products for diabetes, obesity, and other metabolic indications. It includes both in-house pharmaceutical manufacturing and outsourced production through contract development and manufacturing organizations (CDMOs), supported by specialized peptide synthesis, purification, formulation, filling, packaging, and quality-control capabilities.

The market scope includes manufacturing technologies, production capacity expansion, process development, analytical testing, regulatory compliance, and supply-chain operations. Key components include peptide APIs, finished-dose formulations, injectable delivery systems, manufacturing equipment, sterile processing, and supporting services. Coverage also extends across branded and emerging GLP-1 therapies, technology platforms, and manufacturing partnerships. Regional analysis typically examines North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa based on production infrastructure, pharmaceutical demand, investment, and regulatory conditions.

The GLP-1 Manufacturing Market has evolved alongside advances in peptide-based drug development and the expanding use of GLP-1 therapies for type 2 diabetes and obesity. Earlier manufacturing activity focused primarily on established diabetes treatments, while increasing clinical adoption broadened production requirements and encouraged pharmaceutical companies to develop larger, more specialized manufacturing capabilities. Growing demand has also strengthened the role of contract manufacturers, peptide synthesis providers, and specialized formulation facilities within the supply chain.

The market is currently expanding as pharmaceutical companies increase production capacity, improve manufacturing efficiency, and strengthen supply-chain resilience to address rising therapeutic demand. Future growth is expected to be supported by expanding obesity treatment, increasing diabetes prevalence, broader patient access, continued clinical development of GLP-1-based therapies, and investment in advanced peptide synthesis and formulation technologies. Capacity expansion, outsourcing, technological innovation, and regulatory-compliant manufacturing infrastructure are expected to remain important factors shaping market development.

The GLP-1 Manufacturing Market is being driven by the rapid expansion of obesity and type 2 diabetes treatment, rising demand for GLP-1 receptor agonists, and increasing patient adoption of injectable and longer-acting therapies. Pharmaceutical companies are investing in additional production capacity, peptide synthesis, formulation, sterile manufacturing, and supply-chain infrastructure to address growing therapeutic requirements. Continued clinical development of GLP-1-based treatments for metabolic and related conditions is also broadening potential applications. Growing outsourcing among drug developers is strengthening demand for contract development and manufacturing organizations with specialized peptide manufacturing capabilities.

Despite strong demand, manufacturers face challenges related to complex peptide production, stringent quality and regulatory requirements, high capital investment, and the need to maintain reliable supplies of specialized raw materials. Scaling production while preserving product quality, process consistency, sterility, and cost efficiency can create operational pressures. Supply-chain constraints, manufacturing lead times, technology requirements, and competition for production capacity may further affect market expansion, particularly as multiple pharmaceutical companies seek to increase output simultaneously.

Significant opportunities exist through expansion of high-capacity manufacturing facilities, advanced peptide synthesis technologies, automation, continuous manufacturing, and improved formulation processes. Contract manufacturing partnerships can provide pharmaceutical companies with additional capacity without requiring equivalent internal investment. Emerging markets also offer opportunities as access to metabolic therapies improves. Manufacturers that strengthen production flexibility, quality systems, technology capabilities, and global supply networks can participate in the expanding GLP-1 manufacturing ecosystem.

The GLP-1 manufacturing landscape is shifting from shortage-driven capacity expansion toward larger, more integrated production networks. In 2025, FDA reported that semaglutide injection shortages had been resolved as manufacturer capacity improved, while localized supply constraints remained. By 2026, manufacturers continued investing in peptide APIs, sterile fill-finish, injector components, and cartridges. India has seen rapid CDMO expansion, although industry reports indicate capacity constraints across peptide and sterile manufacturing.

Technology trends increasingly center on scalable peptide synthesis, advanced purification, analytical characterization, sterile processing, and oral peptide formulation. Manufacturing is also becoming more closely integrated with drug-device development as injectable GLP-1 products require reliable delivery systems. In September 2026, FDA held a workshop covering synthetic and recombinant manufacturing, impurity profiling, oral peptide formulation, absorption enhancement, and drug-device quality considerations, highlighting the industry's expanding technical requirements.

Regulatory oversight is simultaneously becoming more stringent. In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, while its September 2026 import alert highlighted CGMP concerns involving foreign-sourced GLP-1 APIs. These developments are increasing emphasis on validated facilities, traceability, quality systems, and compliant sourcing. Meanwhile, major manufacturers continue expanding domestic capacity, including Eli Lilly's planned Houston API facility, reinforcing the regionalization of GLP-1 manufacturing.

GLP-1 manufacturing relies on advanced peptide synthesis, purification, formulation, sterile processing, and analytical characterization technologies. Key technical requirements include control of peptide-related impurities, identity, purity, and structural attributes. USP General Chapters <1503> and <1504> provide science-based recommendations for quality attributes of synthetic peptide drug substances and their starting materials. USP also maintains standards for peptide mapping, while its 2025 GLP-1 resources introduced analytical reference materials for products including semaglutide and liraglutide.

Technological advancement is increasingly focused on advanced manufacturing, process analytical technology, automation, continuous manufacturing, and improved analytical methods. FDA's Emerging Technology Program supports evaluation of technologies such as continuous manufacturing, process analytical technology, distributed manufacturing, and artificial intelligence. For sterile GLP-1 products, manufacturers must comply with applicable FDA CGMP requirements, including validated processes, appropriate environmental controls, testing, and quality systems. FDA also published revised 2026 draft product-specific guidances covering peptide products including semaglutide and liraglutide, strengthening the regulatory framework for peptide manufacturing and quality assessment.

GLP-1 manufacturing is governed by pharmaceutical quality and safety requirements applicable to active pharmaceutical ingredients (APIs) and finished drug products. In the United States, manufacturers must comply with FDA Current Good Manufacturing Practice (CGMP) requirements under 21 CFR Parts 210 and 211, covering facilities, equipment, production controls, testing, documentation, and quality systems. FDA also regulates compounding under Sections 503A and 503B of the FD&C Act. In 2026, FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, reflecting tighter controls on compounded GLP-1 products.

For products intended for Europe, manufacturers must comply with EU GMP requirements regardless of manufacturing location. Requirements include appropriate manufacturing authorisation, qualified facilities, validated processes, quality systems, documentation, and regulatory inspections. EU GMP Annex 1 establishes specific requirements for sterile medicinal-product manufacturing, which is particularly relevant to injectable GLP-1 therapies. FDA also applies CGMP requirements to GLP-1 APIs, including foreign-sourced materials, with regulatory oversight covering manufacturing controls and inspection compliance.

Semaglutide held the highest share of the GLP-1 Manufacturing Market by type in 2026, accounting for 34% of the market. Its position reflects extensive manufacturing activity associated with diabetes and obesity treatments, supported by growing demand for peptide-based medicines, expanding treatment adoption, and investments in active pharmaceutical ingredient (API) production and finished-dose capacity. Manufacturers are focusing on production efficiency, quality control, and scalable processes to meet pharmaceutical supply requirements. Semaglutide manufacturing also benefits from its established commercial presence and broad therapeutic applications, making it an important contributor to industry production volumes and capacity planning.

Tirzepatide represented the second-highest share, at 30% in 2026, supported by increasing demand for advanced incretin-based therapies and expanding manufacturing requirements. Its applications in diabetes and weight management are encouraging investments in peptide synthesis, formulation, and production infrastructure. The remaining categories include liraglutide, dulaglutide, and exenatide, which continue to contribute to manufacturing activity through established therapeutic applications and existing product portfolios. Collectively, these product types support diversified production capabilities, supply continuity, and the development of manufacturing processes across the GLP-1 pharmaceutical industry.

In-house manufacturing accounted for the highest share of the GLP-1 Manufacturing Market by manufacturing type in 2026, representing 62%. Pharmaceutical companies increasingly rely on internal production capabilities to maintain control over manufacturing quality, process development, regulatory compliance, and supply-chain operations. Growing demand for GLP-1 therapies is encouraging investment in dedicated peptide production facilities, API manufacturing, formulation technologies, and fill-finish infrastructure. Internal manufacturing also enables companies to protect process expertise, coordinate production schedules, and support product development. These capabilities remain strategically important as manufacturers expand capacity to address rising demand for diabetes and obesity treatments.

Contract manufacturing (CDMO) held the second-highest share, accounting for 38% in 2026. Demand for outsourced manufacturing is supported by the need for flexible production capacity, specialized peptide manufacturing expertise, and reduced infrastructure investment. CDMOs provide services across process development, API synthesis, formulation, analytical testing, and commercial-scale production. Their capabilities help pharmaceutical and biotechnology companies accelerate manufacturing expansion and manage capacity constraints. The segment also supports companies seeking external technical expertise and scalable production arrangements. Both manufacturing models contribute to industry capacity, operational flexibility, and the reliable supply of GLP-1 medicines.

Diabetes management accounted for the highest share of the GLP-1 Manufacturing Market by application in 2026, representing 52%. Manufacturing demand is supported by the continued use of GLP-1 therapies for type 2 diabetes, increasing treatment adoption, and the need for reliable pharmaceutical supply. Producers are expanding peptide synthesis, formulation, and finished-dose manufacturing capabilities to serve established therapeutic markets. Consistent product quality, regulatory compliance, and efficient production processes remain essential to meeting pharmaceutical requirements. Diabetes management continues to underpin manufacturing activity through established clinical applications, sustained medicine demand, and ongoing investments in production infrastructure and supply-chain resilience.

Obesity and weight management represented the second-highest application share, at 38% in 2026. Rising demand for pharmacological weight-management treatments is encouraging manufacturers to expand production capacity, improve process efficiency, and strengthen supply networks. This application supports investments in peptide-based formulations, injectable drug production, and advanced fill-finish operations. Cardiovascular risk reduction represents the remaining application, contributing to manufacturing requirements through the broader therapeutic use of GLP-1 medicines. Together, these applications support diversified production demand and encourage manufacturers to develop scalable, quality-focused processes. Expanding therapeutic use also creates opportunities for pharmaceutical companies and manufacturing partners to strengthen capacity, technology capabilities, and long-term supply arrangements.

Pharmaceutical companies accounted for the highest share of the GLP-1 Manufacturing Market by end use in 2026, representing 55%. Their substantial manufacturing requirements are driven by the development, commercialization, and supply of GLP-1 medicines for diabetes and obesity management. These companies invest in peptide production, API processing, formulation, quality assurance, and finished-dose manufacturing to support product portfolios and regulatory requirements. Expanding therapeutic demand is also encouraging investments in production facilities, advanced manufacturing technologies, and supply-chain capabilities. Pharmaceutical companies remain central to market activity through their manufacturing infrastructure, research capabilities, commercialization networks, and strategic capacity expansion.

Contract manufacturing organizations represented the second-highest share, accounting for 30% in 2026. Their role is expanding as pharmaceutical and biotechnology companies seek specialized production expertise, additional capacity, and flexible manufacturing arrangements. Contract manufacturers provide peptide synthesis, process development, formulation, quality testing, and commercial-scale production services. Biotechnology companies constitute the remaining end-use category, contributing through drug discovery, clinical development, and the advancement of innovative GLP-1 therapies. These organizations require specialized manufacturing capabilities to support development and commercialization activities. Collectively, all three end-use groups drive investment in production infrastructure, technical expertise, quality systems, and scalable manufacturing operations across the GLP-1 industry.

Asia Pacific accounted for 24% of the GLP-1 Manufacturing Market in 2026, with growth supported by expanding pharmaceutical manufacturing capabilities, increasing healthcare demand, and investments in biotechnology infrastructure. Countries such as China, India, Japan, and South Korea contribute to the region's pharmaceutical production ecosystem through established manufacturing facilities, research capabilities, and developing peptide production expertise. Rising demand for diabetes and obesity treatments is encouraging investments in active pharmaceutical ingredient production, formulation technologies, and scalable manufacturing infrastructure. Pharmaceutical companies are focusing on process optimization, automation, quality control, and production efficiency to strengthen supply capabilities. Contract manufacturing also creates opportunities for regional producers to serve domestic and international pharmaceutical customers. The region's manufacturing ecosystem, skilled workforce, and expanding healthcare infrastructure support its growing significance in global GLP-1 production.

North America held the highest regional share, accounting for 39% of the GLP-1 Manufacturing Market in 2026. Its position reflects established pharmaceutical infrastructure, substantial biotechnology investment, advanced research capabilities, and significant demand for GLP-1 therapies. The United States plays an important role through pharmaceutical innovation, drug development, commercial manufacturing, and investments in production capacity. Growing demand for diabetes and obesity treatments is encouraging manufacturers to expand peptide synthesis, formulation, sterile filling, and packaging capabilities. Technology adoption includes advanced process control, manufacturing automation, analytical testing, and quality management systems. Pharmaceutical companies are also strengthening supply-chain resilience and expanding production infrastructure to address manufacturing requirements. Contract manufacturing organizations contribute specialized production expertise and additional capacity. North America's established pharmaceutical ecosystem, research investment, and commercial production capabilities reinforce its importance in the global GLP-1 manufacturing landscape.

Europe represented 25% of the GLP-1 Manufacturing Market in 2026, supported by established pharmaceutical manufacturing networks, biotechnology research, and advanced production infrastructure. Countries including Denmark, Germany, Switzerland, France, and the United Kingdom contribute through pharmaceutical innovation, peptide manufacturing expertise, and specialized production facilities. Increasing demand for diabetes and obesity treatments is encouraging manufacturers to strengthen API production, formulation, and finished-dose manufacturing capabilities. Regulatory compliance, product quality, and manufacturing consistency remain central considerations across regional production operations. Companies are adopting process automation, advanced analytical technologies, and efficient manufacturing systems to improve operational performance. Contract development and manufacturing organizations also support pharmaceutical companies requiring specialized production capabilities. Europe's established research environment, skilled technical workforce, and pharmaceutical manufacturing expertise contribute to regional market development and its continuing role in international GLP-1 medicine supply chains.

The Middle East and Africa accounted for 6% of the GLP-1 Manufacturing Market in 2026. Regional development is supported by healthcare infrastructure investments, pharmaceutical localization initiatives, and growing interest in expanding domestic medicine production. Countries in the Gulf Cooperation Council are investing in healthcare capacity, pharmaceutical infrastructure, and advanced medical technologies, while selected African markets are developing pharmaceutical manufacturing capabilities. Increasing demand for diabetes and obesity treatments creates opportunities for pharmaceutical distribution, local production partnerships, and contract manufacturing arrangements. Technology adoption includes modern pharmaceutical production equipment, quality management systems, and improved manufacturing processes. Regional manufacturers and international pharmaceutical companies can support supply development through licensing, technology transfer, and strategic partnerships. Infrastructure development, regulatory harmonization, and investment in specialized production capabilities remain important factors shaping the region's manufacturing potential.

Latin America represented 6% of the GLP-1 Manufacturing Market in 2026, supported by pharmaceutical industry development, healthcare investment, and increasing demand for treatments addressing metabolic disorders. Brazil and Mexico contribute to the regional pharmaceutical manufacturing landscape through established production facilities, domestic medicine markets, and industry capabilities. Growing demand for diabetes and obesity therapies is creating opportunities to expand pharmaceutical production, strengthen distribution networks, and develop manufacturing partnerships. Regional companies are exploring production modernization, improved quality systems, and specialized pharmaceutical manufacturing capabilities to address evolving market requirements. Contract manufacturing and technology transfer arrangements can support capacity development and access to advanced production expertise. Regulatory alignment, investment availability, and infrastructure expansion influence regional manufacturing progress. Latin America's pharmaceutical ecosystem and expanding healthcare requirements support its contribution to the global GLP-1 manufacturing industry.

Competition in GLP-1 manufacturing is increasingly centered on production scale, supply reliability, product formats, manufacturing technology, and geographic reach. Major producers are expanding API, aseptic processing, fill-finish, packaging, and device capabilities, while product differentiation is extending beyond injectable therapies toward oral GLP-1 formulations. Novo Nordisk is expanding manufacturing across the US, Europe, China, Brazil, and Ireland, including additional capacity for oral GLP-1 products. Eli Lilly is similarly expanding domestic API and peptide manufacturing infrastructure.

Business strategies include large-scale capital investment, acquisitions, external manufacturing partnerships, multi-region sourcing, and adoption of advanced manufacturing technologies. Lilly reports using digital twins and AI-driven visual inspection in manufacturing, while Novo Nordisk highlights continuous production technology for API scalability and yield optimization. Competitive differentiation also depends on regulatory-compliant facilities, validated quality systems, certifications and inspections, reliable API and raw-material sourcing, and supply-chain redundancy. Organic inputs are relevant mainly through the sourcing and control of biological or fermentation-derived manufacturing materials rather than as a separate competitive category.

The competitive landscape is led by Novo Nordisk and Eli Lilly, whose semaglutide and tirzepatide portfolios drive large-scale API, formulation, fill-finish, and delivery-device manufacturing. Novo is expanding oral and injectable capacity across the US, Europe, Brazil, China and Denmark, including new oral-GLP-1 capacity in Ireland. Lilly is expanding manufacturing for Mounjaro, Zepbound and next-generation incretin therapies, including additional US investment. Zealand Pharma focuses on peptide-based metabolic medicines, while Sanofi, AstraZeneca, Boehringer Ingelheim, Novartis and Pfizer maintain broader metabolic or peptide-development capabilities.

The manufacturing ecosystem is supported by CDMOs including Catalent, Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher, Siegfried, Recipharm, Piramal Pharma Solutions, CordenPharma, Bachem and Polypeptide Group. Their strengths include peptide or biologics development, API and drug-product manufacturing, analytical services, sterile processing, and scalable global capacity. Bachem is specifically expanding peptide manufacturing expertise and has evaluated large-scale GLP-1 synthesis approaches. Partnerships, capacity expansion, GMP-compliant operations, process technology, supply-chain diversification and geographic manufacturing networks remain central competitive strategies.

·         Novo Nordisk

·         Eli Lilly And Company

·         Sanofi

·         Astrazeneca

·         Boehringer Ingelheim

·         Novartis

·         Pfizer

·         Zealand Pharma

·         Catalent

·         Lonza

·         Samsung Biologics

·         Wuxi Biologics

·         Thermo Fisher Scientific

·         Siegfried Holding

·         Recipharm

·         Piramal Pharma Solutions

·         Novartis Sandoz

·         Cordenpharma

·         Bachem

·         Polypeptide Group

·         January 21, 2026 – Samsung Biologics: FY2025 revenue of KRW 4,557 billion (~4.557 trillion), reflecting stable operations, expanded manufacturing utilization, and robust client demand.

·         January 28, 2026 – Lonza: FY2025 sales of CHF 6,531 million (6.531 billion), up 19.2% AER / 21.7% CER, with strong CDMO growth and continued new-business momentum.

·         January 29, 2026 – Thermo Fisher Scientific: FY2025 revenue of $44.56 billion, up 4%, with continued growth across life-science and pharma-services businesses.

·         February 3–4, 2026 – Novo Nordisk: 2025 sales of DKK 309.1 billion (309,064 million). Obesity-care sales increased 26% (in DKK), driven by continued manufacturing expansion supporting the obesity/diabetes portfolio.

·         February 4, 2026 – Eli Lilly: FY2025 revenue of $65.179 billion. Mounjaro sales reached $22.965 billion; Zepbound sales reached $13.542 billion. Lilly also reported expanded manufacturing capacity.

·         February 20, 2026 – Siegfried: 2025 net sales of CHF 1,327.8 million (1.3278 billion), with continued investment in US drug-substance manufacturing capacity.

·         February 23, 2026 – Eli Lilly: FDA approved a label expansion for the Zepbound KwikPen (four-dose, single-patient use), adding a new delivery format for tirzepatide. — minor caveat: the underlying FDA approval is dated Jan. 20, 2026; Lilly's public announcement came Feb. 23, 2026.

·         March 12, 2026 – Bachem: 2025 sales of CHF 695.1 million, up 14.8% (19.2% in local currencies), supporting continued peptide-manufacturing expansion.

·         March 24, 2026 – WuXi Biologics: 2025 revenue of RMB 21.8 billion, up 16.7%, with expanded manufacturing capacity, higher utilization, and strengthened CRDMO capabilities.

·         February 17, 2026 – CordenPharma: 2025 net sales of €960 million, with more than 40 new customer projects initiated or advanced during the year.

The GLP-1 Manufacturing Market is expected to maintain strong expansion as pharmaceutical companies increase production to address sustained demand for obesity and diabetes therapies. Major opportunities are emerging in peptide API production, sterile fill-finish, delivery devices, oral formulations, and contract manufacturing. In 2026, Eli Lilly broke ground on a $6.5 billion Houston API facility for its oral GLP-1 medicine, while its broader manufacturing network is being expanded to improve supply resilience.

Future development will increasingly emphasize higher manufacturing efficiency, multi-region capacity, advanced peptide technologies, and diversified supply chains. Novo Nordisk highlights continuous production technology for API scalability and yield optimization, while Lilly is applying digital twins and AI-based inspection in manufacturing. Key challenges include capital intensity, specialized workforce requirements, regulatory compliance, capacity constraints, and the need to maintain consistent quality while rapidly scaling production.